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SHORT COMMUNICATION
Lobular panniculitis after subcutaneous administration of Interleukin-2
(IL-2), and its exacerbation during intravenous therapy with IL-2
J.W. Baars', J.L.L.M. Coenen', J. Wagstaf, P. van der Valk2 & H.M. Pinedo'
'Department ofMedical Oncology and 2Department ofPathology, Free University Hospital, Amsterdam, The Netherlands.
Summary Interleukin-2 (IL-2) is now registered for the treatment of renal cell carcinoma in a number of
European countries. The subcutaneous (sc) route of administration is being used increasingly because of its
better toxicity profile compared with higher dose intravenous (iv) protocols. We report here a patient who
developed a lobular panniculitis at the site of sc IL-2 injection which prevents continuation of sc therapy.
Subsequent administration of the same IL-2 dose by iv injection caused recurrence of the problem again
necessitating discontinuation of IL-2 treatment.
The subcutaneous (sc) administration of IL-2 has recently
received much attention, and has been reported to be less
toxic and probably equally efficacious as the intravenous (iv)
schedules (Atzpodien et al., 1990). One of the observed side-
effects was local irritation with redness and swelling at the
IL-2 injection sites, which has been reported to be tolerable
to the patients (Atzpodien et al., 1990).
We observed a lobular panniculitis during sc treatment
with IL-2, which was exacerbated during subsequent iv IL-2
administration.
A 40 year old woman with metastatic renal cell cancer was
treated with 18 x 106 International Units (IU) IL-2/m2/day
(Eurocetus BV, Amsterdam) by sc injection for 5 days. The
patient experienced pain at the injection sites on her left
thigh following the last day of treatment. Three days there-
after she had to be admitted to hospital because of severe
pain in the left leg, accompanied by redness, swelling, stiff-
ness in the thigh and fever. It was thought that she might
have a cellulitis of her left leg. Blood cultures were taken and
the patient was treated with flucloxacillin. The blood cultures
remained sterile. The redness, swelling and stiffness of the left
leg gradually declined. Because the patient had also experi-
enced rather severe local reactions at other IL-2 injection
sites, it was decided to treat her further with an iv bolus
schedule of 18 x 106 IU IL-2/m2/day for 5 days after 3 weeks
rest. During this cycle the pain at the former injection sites
recurred especially on the left thigh. A biopsy was taken of
this region, which showed small lymphocytic infiltrates
around the blood vessels of the epidermis without vasculitis.
In the subcutaneous fatty tissue an inflammatory process was
observed, which consisted mainly of T cells, macrophages
and eosinophils. A small percentage of T cells were CD25
positive (0 chain of the IL-2 receptor). The majority of the T
cells were HLA-DR negative. The infiltrate contained equal
numbers of CD4 and CD8 positive cells and was located in
the lobuli of the fatty tissue. Fat necrosis was present in
some places (Figure 1). The histology resembled that of the
relapsing nodular non-suppurative panniculitis (Weber-Chris-
tian disease) (Lever & Schaumber-Lever, 1990). This disease
is characterised by the appearance of crops of tender nodules
and plaques in the subcutaneous fat, usually in association
with mild fever (Lever & Schaumberg-Lever, 1990). The
lower extremities are predominantly involved. The patho-
genesis of the disease is unknown. An immune mechanism
may be responsible, because high levels of circulating
immune complexes have been recorded in these patients
(Lever & Schaumberg-Lever, 1990). Our patient showed,
however, no elevated immunoglobulins or circulating immune
complexes. In addition, no antibodies against IL-2 could be
detected. This patient shows that severe local reactions at
IL-2 injection sites can occur during subcutaneous IL-2 treat-
ment, which necessitates interruption of IL-2 treatment.
Cutaneous toxicities due to intravenously administered IL-2
include macular erythema, pruritis and desquamation (Gas-
pari et al., 1987). The histologic changes observed were non-
specific, consisting of lymphoid cells surrounding blood
vessels in the papillary dermis with fewer of these cells in the
epidermis (Gaspari et al., 1987).
Sporadic cases of IL-2 associated erythema nodosum, fatal
pemphigus vulgaris (IL-2 + Interferon-a) and life threatening
bullous skin lesions (IL-2, concomitant administration of
antibiotics) have been reported (Weinstein et al., 1987; Mier
et al., 1988; Ramseur et al., 1989; Staunton et al., 1991).
As far as we know, the complication reported herein has
not yet been described in the literature. The pathogenesis
needs to be further elucidated. The local production of cyto-
kines, local stimulation of lymphocytes, macrophages and
other antigen presenting cells might all play a contributary
role.
Figure 1 Skin biopsy showing infiltrates within the lobules of the
subcutaneous fat (lobular panniculitis). Inset shows foam cells
among the inflammatory infiltrate in which lymphocytes pre-
dominate.
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